How Is The Market Feeling About Iovance Biotherapeutics?
Iovance Biotherapeutics's (NYSE:IOVA) short percent of float has risen 3.31% since its last report. The company recently reported that it has 56.42 million shares sold short, which is 22.5% of all
Iovance Biotherapeutics (NASDAQ:IOVA) Adds US$386m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 67%
This week we saw the Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) share price climb by 19%. But that is little comfort to those holding over the last half decade, sitting on a big loss. Indeed,
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $28
Stifel analyst Benjamin Burnett maintains $Iovance Biotherapeutics(IOVA.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 36.9
Stifel Nicolaus Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
Is Iovance Biotherapeutics a Millionaire Maker?
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday.Shares of Methode Electronics, Inc. (NYSE:MEI) rose sharply during Thursday's session after the company
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Stocks Loved by Analysts?
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright analyst Joseph Pantginis maintains $Iovance Biotherapeutics(IOVA.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rat
Is It Too Late to Buy Iovance Biotherapeutics Stock?
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced MelanomaSAN CARLOS, Calif
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delive
Iovance Biotherapeutics Is Maintained at Market Outperform by JMP Securities
Iovance Biotherapeutics Is Maintained at Market Outperform by JMP Securities
JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating
Iovance Biotherapeutics (IOVA) has an average buy rating and a price target range of $19 to $34, according to analysts polled by Capital IQ.
JMP Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $23
JMP Securities analyst Reni Benjamin maintains $Iovance Biotherapeutics(IOVA.US)$ with a buy rating, and adjusts the target price from $25 to $23.According to TipRanks data, the analyst has a success
Bullish Iovance Biotherapeutics Insiders Loaded Up On US$74.9m Of Stock
Quite a few insiders have dramatically grown their holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) over the past 12 months. An insider's optimism about the company's prospects is a positive si
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
Iovance Biotherapeutics: A Strong Buy on Robust Clinical Data and Market Potential
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics with a Buy and maintains $32 price target.
Iovance Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 254.96% HC Wainwright & Co. $32 → $32 Reiterates Buy → Buy 05/24/2024 254.96% HC Wainwright & C